www.engrail.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $416.09MM
Engrail Therapeutics is a pharmaceutical company focused on developing precision-targeted therapies striving to transform the lives of patients suffering from severe and life-limiting neurological, neuropsychiatric, and neurodevelopmental disorders. The company is seeking to leverage scientific insights into molecular mechanisms and neurocircuitry with the goal of advancing the development of novel treatments aimed at addressing unmet medical needs. Engrail Therapeutics was founded by Stephen Cunningham and Vikram Sudarsan in 2019 and is headquartered in San Diego, CA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
03/19/2024 | Series B-2 | $36.56MM | $xx.xx | $263.11MM | Abrdn Inc, Eight Roads Ventures, Forbion, F-Prime Capital, Longwood Fund, Norwest Venture Partners, Pivotal Life Sciences, Red Tree Venture Capital, Rivervest Venture Partners, Ysios Capital | |
Price per Share
$xx.xx
Shares Outstanding
43,151,767
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Abrdn Inc, Eight Roads Ventures, Forbion, F-Prime Capital, Longwood Fund, Norwest Venture Partners, Pivotal Life Sciences, Red Tree Venture Capital, Rivervest Venture Partners, Ysios Capital
|
||||||
03/19/2024 | Series B-1 | $120.44MM | $xx.xx | $263.11MM | Abrdn Inc, Eight Roads Ventures, Forbion, F-Prime Capital, Longwood Fund, Norwest Venture Partners, Pivotal Life Sciences, Red Tree Venture Capital, Rivervest Venture Partners, Ysios Capital | |
Price per Share
$xx.xx
Shares Outstanding
113,731,655
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Abrdn Inc, Eight Roads Ventures, Forbion, F-Prime Capital, Longwood Fund, Norwest Venture Partners, Pivotal Life Sciences, Red Tree Venture Capital, Rivervest Venture Partners, Ysios Capital
|
||||||
08/03/2021 | Series A-1A | $5.01MM | $xx.xx | $180.23MM | Nan Fung Group, Pivotal Life Sciences | |
Price per Share
$xx.xx
Shares Outstanding
4,558,518
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Nan Fung Group, Pivotal Life Sciences
|
||||||
08/03/2021 | Series A-1B | $4.41MM | $xx.xx | $180.23MM | Nan Fung Group, Pivotal Life Sciences | |
Price per Share
$xx.xx
Shares Outstanding
3,641,171
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Nan Fung Group, Pivotal Life Sciences
|
||||||
08/03/2021 | Series A-1C | $4.96MM | $xx.xx | $180.23MM | Nan Fung Group, Pivotal Life Sciences | |
Price per Share
$xx.xx
Shares Outstanding
3,723,925
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Nan Fung Group, Pivotal Life Sciences
|
||||||
08/03/2021 | Series A-2A | $4.96MM | $xx.xx | $180.23MM | Nan Fung Group, Pivotal Life Sciences | |
Price per Share
$xx.xx
Shares Outstanding
3,103,271
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Nan Fung Group, Pivotal Life Sciences
|
||||||
08/03/2021 | Series A-2B | $5.51MM | $xx.xx | $180.23MM | Nan Fung Group, Pivotal Life Sciences | |
Price per Share
$xx.xx
Shares Outstanding
2,873,399
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Nan Fung Group, Pivotal Life Sciences
|
||||||
08/03/2021 | Series A-2C | $7.16MM | $xx.xx | $180.23MM | Nan Fung Group, Pivotal Life Sciences | |
Price per Share
$xx.xx
Shares Outstanding
3,248,184
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Nan Fung Group, Pivotal Life Sciences
|
||||||
06/18/2020 | Series A | $6.09MM | $xx.xx | $53.33MM | Nan Fung Group, Pivotal Life Sciences | |
Price per Share
$xx.xx
Shares Outstanding
6,085,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Nan Fung Group, Pivotal Life Sciences
|